|
|
| | 2-Pyridinecarboxamide, N-[2-[trans-4-[[4-[[trans-3-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]cyclobutyl]oxy]-1-piperidinyl]methyl]cyclohexyl]-6-(1-hydroxy-1-methylethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)- Basic information |
| | 2-Pyridinecarboxamide, N-[2-[trans-4-[[4-[[trans-3-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]cyclobutyl]oxy]-1-piperidinyl]methyl]cyclohexyl]-6-(1-hydroxy-1-methylethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)- Chemical Properties |
| density | 1.53±0.1 g/cm3(Predicted) | | pka | 10.77±0.40(Predicted) |
| | 2-Pyridinecarboxamide, N-[2-[trans-4-[[4-[[trans-3-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]cyclobutyl]oxy]-1-piperidinyl]methyl]cyclohexyl]-6-(1-hydroxy-1-methylethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)- Usage And Synthesis |
| Uses | KTX-955 is an antumor and effective IRAK4 degrader, with DC50 values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively[1]. KTX-955 is composed of CRBN ligand (blue part) Pomalidomide (HY-10984) and target protein ligand (red part) IRAK4-IN-20 (HY-150735). | | IC 50 | IRAK4: 5 nM (IC50) | | References | [1] Matthew Weiss. Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications. Northeastern Section, ACS (NESACS). [2] Nello Mainolfi, et al. Irak degraders and uses thereof. WO2020264499A1 |
| | 2-Pyridinecarboxamide, N-[2-[trans-4-[[4-[[trans-3-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]cyclobutyl]oxy]-1-piperidinyl]methyl]cyclohexyl]-6-(1-hydroxy-1-methylethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)- Preparation Products And Raw materials |
|